Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy

Molecular Therapy

Volumn 18, Issue 4, 2010, Pages 828-834

  Chen, Yunching ^a   Wu, Jinzi J ^b   Huang, Leaf ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b Ambrilia Biopharma Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARGINYLGLYCYLARGININE; DNA; DOXORUBICIN; LIPOSOME; MICROSOMAL AMINOPEPTIDASE; MYC PROTEIN; NANOPARTICLE; PEPTIDE; POLYCATION; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG STRUCTURE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; SOLID TUMOR; THERAPY EFFECT; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR ENDOTHELIUM;

MUS;

EID: 77950516882     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.291     Document Type: Article

References (24)

1. Baudino, TA, McKay, C, Pendeville-Samain, H, Nilsson, JA, Maclean, KH, White, EL et al. (2002). c-myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 16: 2530-2543.
2. Abaza, MS, Al-Saffar, A, Al-Sawan, S and Al-Attiyah, R (2008). c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumour Biol 29: 287-303.
3. Pastorino, F, Brignole, C, Marimpietri, D, Pagnan, G, Morando, A, Ribatti, D et al. (2003). Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res 9: 4595-4605. (Pubitemid 37248420)
4. Xia, Z, Zhu, Z, Zhang, L, Royal, C, Liu, Z, Chen, Q et al. (2008). Specifc reversal of MDR1/P-gp-dependent multidrug resistance by RNA interference in colon cancer cells. Oncol Rep 20: 1433-1439.
5. Yadav, S, van Vlerken, LE, Little, SR and Amiji, MM (2009). Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol 63: 711-722.
6. Zhao, P, Zhang, Y, Sun, M and He, Y (2008). Reversion of multidrug resistance in human glioma by RNA interference. Neurol Res 30: 562-566. (Pubitemid 352032551)
7. Bagalkot, V, Farokhzad, OC, Langer, R and Jon, S (2006). An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 45: 8149-8152. (Pubitemid 44974149)
8. Minotti, G, Menna, P, Salvatorelli, E, Cairo, G and Gianni, L (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229. (Pubitemid 38720829)
9. Li, SD, Chen, YC, Hackett, MJ and Huang, L (2008). Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 16: 163-169.
10. Li, SD, Chono, S and Huang, L (2008). Effcient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 16: 942-946. (Pubitemid 351587105)
11. Chen, Y, Sen, J, Bathula, SR, Yang, Q, Fittipaldi, R and Huang, L (2009). Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm 6: 696-705.
12. Eckel, R, Ros, R, Ros, A, Wilking, SD, Sewald, N and Anselmetti, D (2003). Identifcation of binding mechanisms in single molecule-DNA complexes. Biophys J 85: 1968-1973. (Pubitemid 37052276)
13. Pasqualini, R, Koivunen, E, Kain, R, Lahdenranta, J, Sakamoto, M, Stryhn, A et al. (2000). Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60: 722-727. (Pubitemid 30094573)
14. Mina-Osorio, P (2008). The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med 14: 361-371.
15. Arap, W, Pasqualini, R and Ruoslahti, E (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380. (Pubitemid 28063372)
16. Curnis, F, Sacchi, A, Borgna, L, Magni, F, Gasparri, A and Corti, A (2000). Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18: 1185-1190.
17. Ellerby, HM, Arap, W, Ellerby, LM, Kain, R, Andrusiak, R, Rio, GD et al. (1999). Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038. (Pubitemid 29439574)
18. Garde, SV, Forté, AJ, Ge, M, Lepekhin, EA, Panchal, CJ, Rabbani, SA et al. (2007). Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 18: 1189-1200. (Pubitemid 47480744)
19. Pastorino, F, Brignole, C, Di Paolo, D, Nico, B, Pezzolo, A, Marimpietri, D et al. (2006). Targeting liposomal chemotherapy via both tumor cell-specifc and tumor vasculature-specifc ligands potentiates therapeutic effcacy. Cancer Res 66: 10073-10082. (Pubitemid 44672061)
20. Pastorino, F, Brignole, C, Marimpietri, D, Cilli, M, Gambini, C, Ribatti, D et al. (2003). Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63: 7400-7409. (Pubitemid 37413482)
21. Corti, A, Curnis, F, Arap, W and Pasqualini, R (2008). The neovasculature homing motif NGR: more than meets the eye. Blood 112: 2628-2635.
22. Priebe, W, Van, NT, Burke, TG and Perez-Soler, R (1993). Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs 4: 37-48. (Pubitemid 23063732)
23. Corti, A and Ponzoni, M (2004). Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci 1028: 104-112. (Pubitemid 40361814)
24. Cui, Z, Han, SJ, Vangasseri, DP and Huang, L (2005). Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm 2: 22-28. (Pubitemid 40314726)